secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001714899-24-000075
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali raises $500M via PIPE at $17.07/share, adds pre-funded warrants
----------------------------------------------------------------------

- Gross proceeds of ~$500M from 3.2M shares at $17.07 and 26M pre-funded warrants at $17.06.
- Proceeds to fund R&D, accelerate BBB-crossing Transport Vehicle technology, and working capital.
- Lead investor is a U.S. healthcare-focused fund; close expected Feb 29, 2024.
- Post-close estimated cash, equivalents, and investments ~$1.5B.
- Investor with >10% ownership can appoint one board nominee under nominating agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000075/0001714899-24-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000075/dnli-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer